NCT06315283CompletedPhase 1
An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants with Schizophrenia
Source: EU CTIS (euclinicaltrials.eu) · Last updated 27 Aug 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- First submitted
- 17 Jan 2024
- Start date
- 19 Jun 2024
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D LLC
- Diseases
- Schizophrenia
- NCT number
- NCT06315283
- EU CT number
- 2023-505664-11-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 18
- 5 sites in 4 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (5)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Goethe University Frankfurt Coordinator of this site? Confirm its status | Frankfurt Am Main | Germany | Completed |
| Complejo Asistencial de Zamora. Hospital Provincial de Zamora Coordinator of this site? Confirm its status | Zamora | Spain | Completed |
| Chu Gabriel Montpied Coordinator of this site? Confirm its status | Clermont-Ferrand | France | Withdrawn |
| Centre Hospitalier Universitaire De Montpellier Coordinator of this site? Confirm its status | Montpellier Cedex 5 | France | Withdrawn |
| Clinic for psychiatry Sveti Ivan Coordinator of this site? Confirm its status | Grad Zagreb | Croatia | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.